EAN News

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

We are happy to announce that our Sustainability Report 2023 is ready to be downloaded via the new Sustainability page of EAN.org.

Watch a full recording of the European Brain Health Summit 2023, held on 9 May, featuring key international voices on precision neurology and the prevention of neurological diseases.

EAN Scientific Committee Chair, Thomas Berger, reports on the new Cost-Conscious Healthcare project, the EAN Science School, and how EAN members can play a part in setting the EAN's scientific course.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.

EAN President, Paul Boon, on the forthcoming Brain Health Summit, EAN advocacy activities, the recent national societies forum, and more.

Our April paper of the month investigates the association between focal epilepsy and risk of incident dementia compared with patients with stroke or migraine and with healthy controls.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for April 2023.

We are proud to announce a new education initiative: the EAN Regional Teaching Session, bringing EAN-organised sessions to your national meeting.

Join our team of leading experts, policymakers and stakeholders on a journey through the European brain health landscape on May 9.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for March 2023.

MSIF’s application to add Multiple Sclerosis treatments to the WHO Essential Medicines List has the potential to put MS higher on the agenda of the WHO and individual countries.

EAN Education Committee Chair, Irena Rektorová, gives an update on new projects, upcoming deadlines, and some exciting additions to existing educational programmes.

Our paper of the month presents the results of a prospective, double-blind, randomised, sham-controlled trial involving 16 centres and investigating the safety and efficacy of unilateral FUSA of the globus pallidus internus in patients with medication-refractory idiopathic PD.

Are you a neurologist whose line of work was affected by the pandemic? We want to hear how COVID-19 has impacted your professional field.